ArticleTherapeutic advances in medical oncology2026
Consolidative thoracic radiotherapy following first-line chemo-immunotherapy in extensive-stage small-cell lung cancer: A systematic review and meta-analysis.
Article in Therapeutic advances in medical oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Immune checkpoint inhibitors (ICIs) combined with first-line platinum-etoposide have changed the standard treatment of extensive-stage small-cell lung cancer (ES-SCLC), yet the role of consolidative thoracic radiotherapy (cTRT) in the chemo-immunotherapy era remains unclear. Objectives: To evaluate the association of cTRT after first-line chemo-immunotherapy with survival outcomes and treatment-related toxicity in ES-SCLC. Design: Systematic review and meta-analysis. Data Sources and Methods: We systematically identified studies evaluating cTRT following first-line chemo-immunotherapy in ES-SCLC. Overall survival (OS) and progression-free survival (PFS) were pooled using hazard ratios (HRs), and safety outcomes were pooled using risk differences (RDs), each with 95% confidence intervals (CIs). Results: Seventeen studies (all non-randomized) involving 2,263 patients were included. cTRT was associated with improved OS (HR 0.63, 95% CI 0.56-0.71; p<0.001; I Conclusion: In ES-SCLC treated with first-line chemo-immunotherapy, cTRT was associated with improved survival and increased localized thoracic toxicity, particularly any-grade pneumonitis and esophagitis, without a significant increase in overall grade ≥3 adverse events. Pending prospective randomized validation, these results could support the use of cTRT after the disease control with first-line chemo-immunotherapy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.